InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
6
T+90 hit rate
33%
T+90 mean return
-3.2%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Patel Sushil, Director. Officer active across 2 companies, notably Replimune Group, Inc.. In total, 19 reports have been published. Split: 0 buy · 6 sells. Total volume traded: €941k. History available since 3 May 2021. The latest transaction was disclosed on 20 May 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations19 total
25,105 shares@ US$8.0619.1% of flowCommon StockSEC:0001104659-25-052143:0
166,667 shares0Common StockSEC:0001104659-25-031835:0
10,000 shares@ US$12.4212.6% of flowCommon StockSEC:0001104659-24-129864:0
5,000 shares@ US$24.8463.0% of flowCommon StockSEC:0001610717-24-000516:0
2,155 shares@ US$16.8018.4% of flowCommon StockSEC:0001610717-24-000394:0
4,248 shares0Common StockSEC:0001610717-24-000374:0
4,800 shares0Common StockSEC:0001610717-24-000361:0
20,194 shares@ US$6.4712.8% of flowCommon StockSEC:0001104659-24-063559:0
2,155 shares@ US$16.8018.6% of flowCommon StockSEC:0001610717-24-000205:0
83,335 shares0Common StockSEC:0001104659-24-043258:0
5,145 shares@ US$24.1112.2% of flowCommon StockSEC:0001104659-23-071772:0
5,200 shares0Common StockSEC:0001610717-23-000131:0
15,575 shares@ US$18.0527.5% of flowCommon StockSEC:0001104659-23-062378:0
40,000 shares0Common StockSEC:0001104659-23-041719:0
10,500 shares0Common StockSEC:0001567619-22-013113:0
10,687 shares@ US$14.590.035% mcap100.0% of flowCommon StockSEC:0001104659-22-062607:0
52,500 shares0Common StockSEC:0001104659-22-042768:0
88,333 shares0Common StockSEC:0001104659-21-061913:0
88,333 shares0Common StockSEC:0001104659-21-061913
19 of 19 declarations
About Patel Sushil
Patel Sushil is the Chief Commercial Officer and Board Member of Replimune Group, Inc. and Revolution Medicines, Inc. In these roles, he is responsible for commercial strategy and business development, contributing to the growth of the companies in the biopharmaceutical sector.
